ABBRATECH, INC.

A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D

ABBRATECH, INC. is a business in national institute of general medical sciences based in Branford, CT.

Profile

ABSTRACT
This Phase II proposal is an ambitious advancement for precision oncology, focusing on
the discovery and validation of T cell receptor mimic antibodies (TCRms) targeting
mutation-associated neoantigens (MANAs) specific to KRAS mutations. More specifically
the KRASG12D mutation in the HLA-A*11:01 allele. This project, rooted in the innovative
'Epivolve' technology, aims to enhance the specificity and efficacy of immunotherapies by
developing novel antibodies that can distinguish between mutant and wild-type KRAS
peptides. The significance of this research lies in its potential to overcome the
longstanding challenge of targeting intracellular oncogenic proteins, which are otherwise
inaccessible to conventional therapies. Upon successful completion, this strategy could
transform the therapeutic landscape for numerous cancers characterized by KRAS
mutations and other neoantigens, offering highly targeted treatments with potentially
fewer off-target effects and significantly improved patient outcomes in the oncology field.

ABBRATECH, INC. is positioned in national institute of general medical sciences, a segment that rewards a clear, focused offering.

The business is associated with Branford, CT.

The company is listed at the SBIR/STTR stage of development.

Its team size is recorded as 1-10 employees.

It has disclosed roughly $1 in funding.

Website: abbratech.com